ArticleFrontiers in psychiatry2026
Artificial intelligence-based diagnostic model for schizophrenia in individuals living with HIV.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schizophrenia is one of the most prevalent severe mental disorders among people living with HIV (PLWH). Delayed diagnosis and misdiagnosis contribute to poor prognosis and substantial economic burden in this population. However, there are currently no validated diagnostic models available for schizophrenia in PLWH. Methods: PLWH attending annual follow-ups at Yunnan Provincial Hospital of Infectious Diseases/Yunnan AIDS Care Center were enrolled. Hematological parameters were compared between PLWH with schizophrenia (HIV-Scz) and those without (HIV-non-Scz) and diagnostic models were constructed using six machine learning algorithms. Model performance was evaluated comprehensively using area under the curve (AUC), accuracy, F1 score, recall, precision, and decision curve analysis. SHapley Additive exPlanations (SHAP) were applied to determine the relative importance of each feature. Results: A total of 186 participants were included in this study, including 62 with clinically confirmed schizophrenia who were receiving antipsychotic treatment at the time of blood sampling. Compared with the HIV-non-Scz group, the HIV-Scz group exhibited significant differences across multiple hematological parameters. Six machine learning models constructed using 28 routine blood parameters demonstrated diagnostic capability, among which the Lasso regression model achieved the best overall performance, with mean AUC (0.966 ± 0.016), F1-score (0.839 ± 0.067), and accuracy (0.897 ± 0.037), together with favorable precision (0.867 ± 0.061) and recall (0.821 ± 0.111). Decision curve analysis indicated that this model provided a higher net benefit within clinically relevant threshold probability ranges. Furthermore, SHAP analysis identified PDW, MPV and MCV as the most influential features contributing to model predictions. Conclusion: Routine hematological parameters may serve as potential diagnostic biomarkers for schizophrenia in PLWH, although medication-related effects in treated patients cannot be excluded.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.